bupropion has been researched along with Obesity in 109 studies
Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
Excerpt | Relevance | Reference |
---|---|---|
" The authors tested the effectiveness of naltrexone-bupropion and behavioral weight loss therapy (BWL), alone and combined, for binge-eating disorder comorbid with obesity." | 9.51 | Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial. ( Fineberg, SK; Grilo, CM; Gueorguieva, R; Ivezaj, V; Lydecker, JA; Moreno, JO, 2022) |
"This study assessed the effects of 32 mg naltrexone sustained release (SR)/360 mg bupropion SR (NB) on body weight in adults with obesity, with comprehensive lifestyle intervention (CLI), for 78 weeks." | 9.24 | Method-of-use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity. ( Fujioka, K; Gilder, K; Halseth, A; Shan, K; Walsh, B, 2017) |
"To determine whether the combination of naltrexone and bupropion increases major adverse cardiovascular events (MACE, defined as cardiovascular death, nonfatal stroke, or nonfatal myocardial infarction) compared with placebo in overweight and obese patients." | 9.22 | Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. ( Bakris, G; Buse, JB; Nissen, SE; Perez, A; Prcela, L; Smith, SR; Wadden, T; Wolski, KE, 2016) |
"To assess the efficacy and safety of 32 mg naltrexone sustained-release (SR)/360 mg bupropion SR (NB) in overweight/obese individuals with type 2 diabetes with or without background oral antidiabetes drugs." | 9.17 | Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. ( Bays, H; Burns, C; Fujioka, K; Greenway, F; Gupta, AK; Hollander, P; Klassen, P; Plodkowski, R, 2013) |
"CONTRAVE Obesity Research-II (COR-II) was a double-blind, placebo-controlled study of 1,496 obese (BMI 30-45 kg/m(2) ) or overweight (27-45 kg/m(2) with dyslipidemia and/or hypertension) participants randomized 2:1 to combined naltrexone sustained-release (SR) (32 mg/day) plus bupropion SR (360 mg/day) (NB32) or placebo for up to 56 weeks." | 9.17 | A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). ( Apovian, CM; Aronne, L; Burns, C; Dunayevich, E; Kim, D; Rubino, D; Still, C; Wyatt, H, 2013) |
" The objective of this study was to perform a randomized placebo-controlled trial to evaluate the short-term efficacy of bupropion for the treatment of BED in overweight and obese women." | 9.17 | Bupropion for overweight women with binge-eating disorder: a randomized, double-blind, placebo-controlled trial. ( Grilo, CM; White, MA, 2013) |
"A sustained-release combination of naltrexone plus bupropion could be a useful therapeutic option for treatment of obesity." | 9.14 | Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. ( Dunayevich, E; Erickson, J; Fujioka, K; Greenway, FL; Guttadauria, M; Kim, DD; Mudaliar, S; Plodkowski, RA, 2010) |
"A combination of sustained release (SR) naltrexone (32 mg/day) and bupropion SR (360 mg/day) plus behavioral counseling was evaluated for the treatment of smoking cessation and mitigation of nicotine withdrawal and weight gain." | 9.14 | An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects. ( Billes, SK; Dunayevich, E; Erickson, JS; Katz, BB; Oskooilar, N; Tollefson, G; Wilcox, CS, 2010) |
"Our objective was to determine whether opioid receptor antagonism (naltrexone) plus pro-opiomelanocortin activation (bupropion) causes greater weight loss than placebo or monotherapy." | 9.14 | Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. ( Cowley, MA; Dunayevich, E; Erickson, J; Fujioka, K; Greenway, FL; Guttadauria, M; Tollefson, G, 2009) |
"Zonisamide and bupropion have been investigated for weight reduction in obese adults." | 9.12 | Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. ( Foust, MS; Gadde, KM; Wagner, HR; Yonish, GM, 2007) |
"Obese adults (body mass index, 30 to 44 kg/m(2)) not currently meeting criteria for major depression but with depressive symptoms (Beck Depression Inventory score 10-30) received bupropion SR 300 mg/d or placebo for 26 weeks with a 500 kcal/d-deficit diet." | 9.10 | Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. ( Allison, DB; Brewer, ER; Buaron, KS; Gadde, KM; Haight, B; Jain, AK; Jamerson, BD; Kaplan, RA; Leadbetter, RA; Metz, A; Richard, N; Wadden, TA, 2002) |
"To critically examine the efficacy of bupropion SR for weight loss." | 9.10 | Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. ( Anderson, JW; Fujioka, K; Gadde, KM; Greenway, FL; McKenney, J; O'Neil, PM, 2002) |
"On the basis of the clinical observations that bupropion facilitated weight loss, we investigated the efficacy and tolerability of this drug in overweight and obese adult women." | 9.09 | Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. ( Drezner, MK; Gadde, KM; Krishnan, KR; Logue, EJ; Maner, LG; Parker, CB; Wagner, HR, 2001) |
"Few studies on combination therapies for the treatment of obesity had been conducted until recently, when two fixed-dose combinations, bupropion-naltrexone ER fixed-dose combination and phentermine-topiramate ER titrated-dose combinations were evaluated in clinical studies that ultimately led to FDA approval." | 8.95 | Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release. ( Halpern, B; Mancini, MC, 2017) |
"Contrave(®) is a combination of naltrexone hydrochloride extended release and bupropion hydrochloride extended release for the treatment of obesity, and is used with lifestyle modification." | 8.93 | Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes. ( Apovian, CM, 2016) |
" Melatonin, liraglutide, and naltrexone/bupropion are examples of drugs with different mechanisms of action that have favorable effects on obesity or medication-related weight gain." | 8.91 | Melatonin, Liraglutide, and Naltrexone/Bupropion for the Treatment of Obesity and Medication-Related Weight Gain. ( Howland, RH, 2015) |
"The mechanism of action of the combination therapy, naltrexone/bupropion (NB), for obesity has not been fully described to date." | 8.90 | Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. ( Billes, SK; Cowley, MA; Sinnayah, P, 2014) |
"This review examines the safety and antiobesity effects of naltrexone and bupropion alone and in combination." | 8.90 | Drug safety evaluation of naltrexone/bupropion for the treatment of obesity. ( Bello, NT; Verpeut, JL, 2014) |
"This review covers the development of naltrexone/bupropion combination therapy for obesity, as well as the published clinical trials on the safety and efficacy of the combination in overweight and obese humans." | 8.87 | Combination therapy with naltrexone and bupropion for obesity. ( Billes, SK; Greenway, FL, 2011) |
"Naltrexone/bupropion is an investigational combination for weight loss and maintenance in patients who are obese or have a BMI ≥ 27 kg/m(2) with comorbid diabetes, hypertension or hyperlipidemia." | 8.87 | Naltrexone/bupropion: an investigational combination for weight loss and maintenance. ( Gwinn, KM; Hurren, KM; Makowski, CT, 2011) |
"Bupropion and naltrexone are centrally active drugs that have shown potential efficacy - alone and in combination - for the treatment of obesity." | 8.85 | Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity. ( Chau, DL; Nguyen, L; Nguyen, Q; Plodkowski, RA; St Jeor, S; Sundaram, U, 2009) |
" While the opioid receptor antagonist naltrexone is associated with minimal weight loss as monotherapy, it does have potential utility in the treatment of obesity when combined with the pro-opiomelanocortin activator bupropion." | 8.85 | Naltrexone for the treatment of obesity: review and update. ( Fujioka, K; Lee, MW, 2009) |
"Contrave, under development by Orexigen Therapeutics Inc for the potential treatment of obesity, is an oral, sustained-release combination of the dopamine and norepinephrine reuptake antagonist bupropion and the opioid antagonist naltrexone." | 8.85 | Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity. ( Padwal, R, 2009) |
"To investigate the changes of circulating levels of all proglucagon-derived peptides (PGDPs) in individuals with overweight or obesity receiving liraglutide (3 mg) or naltrexone/bupropion (32/360 mg), and to explore the association between induced changes in postprandial PGDP levels and body composition, as well as metabolic variables, after 3 and 6 months on treatment." | 8.31 | Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long ( Argyrakopoulou, G; Bontozoglou, N; Kalra, B; Kokkinos, A; Konstantinidou, SK; Kouvari, M; Kumar, A; Kumar, M; Kyriakopoulou, K; Mantzoros, CS; Simati, S; Stefanakis, K, 2023) |
", with naltrexone) has been explored as an anti-obesity strategy, and is particularly effective when co-administered with dual inhibitors of dopamine and norepinephrine reuptake (e." | 7.79 | Effects of amylin and bupropion/naltrexone on food intake and body weight are interactive in rodent models. ( Athanacio, J; Clapper, JR; D'Souza, L; Griffin, PS; Parkes, DG; Roth, JD; Wittmer, C, 2013) |
"The combination of bupropion and naltrexone is one of the most promising new possibilities for the treatment of obesity in an era of increasing prevalence of this disease and decreasing options for its pharmacological management." | 7.77 | Bupropion/naltrexone fixed-dose combination for the treatment of obesity. ( Faria, AM; Halpern, A; Halpern, B, 2011) |
"Weight loss is associated with improved quality of life in some, but not all, weight loss trials." | 6.80 | Patient-reported quality of life in a randomized placebo-controlled trial of naltrexone/bupropion for obesity. ( Chen, S; Gilder, K; Greenway, FL; Klassen, P; Kolotkin, RL, 2015) |
"Insulin resistance was also assessed at the end." | 6.71 | Weight gain and cardiovascular risk factors during smoking cessation with bupropion or nicotine. ( Alvarez, F; Botella-Carretero, JI; Cantarero, M; Escobar-Morreale, HF; García, G; Martín, I; Valero, AM; Varela, C, 2004) |
"The treatment with liraglutide 3." | 6.66 | New-generation anti-obesity drugs: naltrexone/bupropion and liraglutide. An update for endocrinologists and nutritionists. ( Barrea, L; Colao, A; Laudisio, D; Muscogiuri, G; Pugliese, G; Savastano, S, 2020) |
"Obesity is an emerging disease worldwide." | 6.50 | Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date. ( Albert, L; Caixàs, A; Capel, I; Rigla, M, 2014) |
"The prevalence of obesity is growing rapidly worldwide, and therefore there is a need for effective treatment strategies." | 6.47 | Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'? ( Hatzitolios, AI; Katsiki, N; Mikhailidis, DP, 2011) |
"Bupropion is a norepinephrine and dopamine uptake inhibitor that has been available for several years for the treatment of depression and aiding smokers to quit." | 6.44 | Bupropion for weight reduction. ( Gadde, KM; Xiong, GL, 2007) |
" The authors tested the effectiveness of naltrexone-bupropion and behavioral weight loss therapy (BWL), alone and combined, for binge-eating disorder comorbid with obesity." | 5.51 | Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial. ( Fineberg, SK; Grilo, CM; Gueorguieva, R; Ivezaj, V; Lydecker, JA; Moreno, JO, 2022) |
"This study assessed the effects of 32 mg naltrexone sustained release (SR)/360 mg bupropion SR (NB) on body weight in adults with obesity, with comprehensive lifestyle intervention (CLI), for 78 weeks." | 5.24 | Method-of-use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity. ( Fujioka, K; Gilder, K; Halseth, A; Shan, K; Walsh, B, 2017) |
"To determine whether the combination of naltrexone and bupropion increases major adverse cardiovascular events (MACE, defined as cardiovascular death, nonfatal stroke, or nonfatal myocardial infarction) compared with placebo in overweight and obese patients." | 5.22 | Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. ( Bakris, G; Buse, JB; Nissen, SE; Perez, A; Prcela, L; Smith, SR; Wadden, T; Wolski, KE, 2016) |
"CONTRAVE Obesity Research-II (COR-II) was a double-blind, placebo-controlled study of 1,496 obese (BMI 30-45 kg/m(2) ) or overweight (27-45 kg/m(2) with dyslipidemia and/or hypertension) participants randomized 2:1 to combined naltrexone sustained-release (SR) (32 mg/day) plus bupropion SR (360 mg/day) (NB32) or placebo for up to 56 weeks." | 5.17 | A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). ( Apovian, CM; Aronne, L; Burns, C; Dunayevich, E; Kim, D; Rubino, D; Still, C; Wyatt, H, 2013) |
" The objective of this study was to perform a randomized placebo-controlled trial to evaluate the short-term efficacy of bupropion for the treatment of BED in overweight and obese women." | 5.17 | Bupropion for overweight women with binge-eating disorder: a randomized, double-blind, placebo-controlled trial. ( Grilo, CM; White, MA, 2013) |
"To assess the efficacy and safety of 32 mg naltrexone sustained-release (SR)/360 mg bupropion SR (NB) in overweight/obese individuals with type 2 diabetes with or without background oral antidiabetes drugs." | 5.17 | Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. ( Bays, H; Burns, C; Fujioka, K; Greenway, F; Gupta, AK; Hollander, P; Klassen, P; Plodkowski, R, 2013) |
" Here, we explore combination therapy with bupropion (BUP), a putative stimulator of melanocortin pathways, and an opioid antagonist, naltrexone (NAL), to antagonize an inhibitory feedback loop that limits sustained weight reduction." | 5.14 | Rational design of a combination medication for the treatment of obesity. ( Anderson, JW; Atkinson, RL; Cowley, MA; Dunayevich, E; Fujioka, K; Gadde, KM; Greenway, FL; Gupta, AK; Guttadauria, M; O'Neil, P; Schumacher, D; Smith, D; Tollefson, GD; Weber, E; Whitehouse, MJ, 2009) |
"Our objective was to determine whether opioid receptor antagonism (naltrexone) plus pro-opiomelanocortin activation (bupropion) causes greater weight loss than placebo or monotherapy." | 5.14 | Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. ( Cowley, MA; Dunayevich, E; Erickson, J; Fujioka, K; Greenway, FL; Guttadauria, M; Tollefson, G, 2009) |
"A sustained-release combination of naltrexone plus bupropion could be a useful therapeutic option for treatment of obesity." | 5.14 | Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. ( Dunayevich, E; Erickson, J; Fujioka, K; Greenway, FL; Guttadauria, M; Kim, DD; Mudaliar, S; Plodkowski, RA, 2010) |
"A combination of sustained release (SR) naltrexone (32 mg/day) and bupropion SR (360 mg/day) plus behavioral counseling was evaluated for the treatment of smoking cessation and mitigation of nicotine withdrawal and weight gain." | 5.14 | An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects. ( Billes, SK; Dunayevich, E; Erickson, JS; Katz, BB; Oskooilar, N; Tollefson, G; Wilcox, CS, 2010) |
"Zonisamide and bupropion have been investigated for weight reduction in obese adults." | 5.12 | Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. ( Foust, MS; Gadde, KM; Wagner, HR; Yonish, GM, 2007) |
"This study evaluated the ability of polymorphisms in five candidate genes to predict weight gain among patients taking bupropion or placebo in a smoking cessation trial." | 5.12 | No evidence for a major role of polymorphisms during bupropion treatment. ( Allison, DB; Berrettini, WH; Hu, J; Lerman, C; Pinto, A; Redden, DT; Restine, SL; Shields, PG, 2006) |
"To critically examine the efficacy of bupropion SR for weight loss." | 5.10 | Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. ( Anderson, JW; Fujioka, K; Gadde, KM; Greenway, FL; McKenney, J; O'Neil, PM, 2002) |
"Obese adults (body mass index, 30 to 44 kg/m(2)) not currently meeting criteria for major depression but with depressive symptoms (Beck Depression Inventory score 10-30) received bupropion SR 300 mg/d or placebo for 26 weeks with a 500 kcal/d-deficit diet." | 5.10 | Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. ( Allison, DB; Brewer, ER; Buaron, KS; Gadde, KM; Haight, B; Jain, AK; Jamerson, BD; Kaplan, RA; Leadbetter, RA; Metz, A; Richard, N; Wadden, TA, 2002) |
"On the basis of the clinical observations that bupropion facilitated weight loss, we investigated the efficacy and tolerability of this drug in overweight and obese adult women." | 5.09 | Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. ( Drezner, MK; Gadde, KM; Krishnan, KR; Logue, EJ; Maner, LG; Parker, CB; Wagner, HR, 2001) |
"Four new medicines-liraglutide, lorcaserin, bupropion/naltrexone, and phentermine/topiramate-have been recently added to the pharmacological arsenal for obesity treatment and could represent important tools to manage this epidemic disease." | 5.01 | Gender-related issues in the pharmacology of new anti-obesity drugs. ( Barrea, L; Cataldi, M; Colao, A; Guida, B; Muscogiuri, G; Savastano, S; Taglialatela, M, 2019) |
" The aim of the present review is to summarize the current data on the eff ects of antiobesity drugs approved in Europe (orlistat, liraglutide 3 mg od and naltrexone/bupropion) on weight loss in patients with PCOS and to discuss their impact on the endocrine, reproductive and metabolic abnormalities of this population." | 4.98 | The Role of Antiobesity Agents in the Management of Polycystic Ovary Syndrome. ( Chatzis, P; Dinas, K; Makris, V; Pratilas, GC; Sotiriadis, A; Tziomalos, K, 2018) |
"Few studies on combination therapies for the treatment of obesity had been conducted until recently, when two fixed-dose combinations, bupropion-naltrexone ER fixed-dose combination and phentermine-topiramate ER titrated-dose combinations were evaluated in clinical studies that ultimately led to FDA approval." | 4.95 | Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release. ( Halpern, B; Mancini, MC, 2017) |
"Contrave(®) is a combination of naltrexone hydrochloride extended release and bupropion hydrochloride extended release for the treatment of obesity, and is used with lifestyle modification." | 4.93 | Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes. ( Apovian, CM, 2016) |
" Phentermine/topiramate ER appeared to have the best overall average weight loss from baseline as well as highest percentages of patients achieving both ≥5% and ≥10% weight loss benchmarks, followed second by naltrexone/bupropion, and then liraglutide, with lorcaserin showing the lowest rates." | 4.93 | A Comparison of New Pharmacological Agents for the Treatment of Obesity. ( Megyeri, J; Nuffer, W; Trujillo, JM, 2016) |
" In BED with obesity or overweight, bupropion may cause mild weight loss without seizures, and chromium may improve glucose regulation." | 4.91 | Psychopharmacologic treatment of eating disorders: emerging findings. ( Guerdjikova, AI; Keck, PE; McElroy, SL; Mori, N, 2015) |
"This review examines the safety and antiobesity effects of naltrexone and bupropion alone and in combination." | 4.90 | Drug safety evaluation of naltrexone/bupropion for the treatment of obesity. ( Bello, NT; Verpeut, JL, 2014) |
"The mechanism of action of the combination therapy, naltrexone/bupropion (NB), for obesity has not been fully described to date." | 4.90 | Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. ( Billes, SK; Cowley, MA; Sinnayah, P, 2014) |
"A short overview of new drugs approved for the treatment of obesity (lorcaserin, phentermine/topiramate combination) as well as those with a perspective for approval as antiobesity drugs (cetilistat, naltrexone/bupropion combination, liraglutide) is presented." | 4.90 | Overview of new antiobesity drugs. ( Hainer, V, 2014) |
"This review covers the development of naltrexone/bupropion combination therapy for obesity, as well as the published clinical trials on the safety and efficacy of the combination in overweight and obese humans." | 4.87 | Combination therapy with naltrexone and bupropion for obesity. ( Billes, SK; Greenway, FL, 2011) |
"Contrave is an investigational fixed-dose combination drug of naltrexone and bupropion currently in Phase III clinical trials for the treatment of obesity." | 4.87 | ACS chemical neuroscience molecule spotlight on contrave. ( Mercer, SL, 2011) |
"Naltrexone/bupropion is an investigational combination for weight loss and maintenance in patients who are obese or have a BMI ≥ 27 kg/m(2) with comorbid diabetes, hypertension or hyperlipidemia." | 4.87 | Naltrexone/bupropion: an investigational combination for weight loss and maintenance. ( Gwinn, KM; Hurren, KM; Makowski, CT, 2011) |
"In March 2010, Orexigen(R) Therapeutics submitted a new drug application (NDA) for approval of naltrexone sustained release (SR)/bupropion SR (Contrave(R)) for the treatment of obesity in the US." | 4.86 | Naltrexone/bupropion: Contrave(R); naltrexone SR/bupropion SR. ( , 2010) |
"Bupropion and naltrexone are centrally active drugs that have shown potential efficacy - alone and in combination - for the treatment of obesity." | 4.85 | Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity. ( Chau, DL; Nguyen, L; Nguyen, Q; Plodkowski, RA; St Jeor, S; Sundaram, U, 2009) |
"Contrave, under development by Orexigen Therapeutics Inc for the potential treatment of obesity, is an oral, sustained-release combination of the dopamine and norepinephrine reuptake antagonist bupropion and the opioid antagonist naltrexone." | 4.85 | Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity. ( Padwal, R, 2009) |
" While the opioid receptor antagonist naltrexone is associated with minimal weight loss as monotherapy, it does have potential utility in the treatment of obesity when combined with the pro-opiomelanocortin activator bupropion." | 4.85 | Naltrexone for the treatment of obesity: review and update. ( Fujioka, K; Lee, MW, 2009) |
" Bupropion is less likely than other antidepressants to cause weight gain and sexual dysfunction, the 2 side effects that are of greatest concern to patients and that have the greatest impact on long-term compliance." | 4.82 | Why isn't bupropion the most frequently prescribed antidepressant? ( Attiullah, N; Baymiller, S; Berlowitz, SL; Boland, RJ; Chelminski, I; Friedman, M; Posternak, MA; Rahman, S; Singer, S; Uy, KK; Zimmerman, M, 2005) |
"To investigate the changes of circulating levels of all proglucagon-derived peptides (PGDPs) in individuals with overweight or obesity receiving liraglutide (3 mg) or naltrexone/bupropion (32/360 mg), and to explore the association between induced changes in postprandial PGDP levels and body composition, as well as metabolic variables, after 3 and 6 months on treatment." | 4.31 | Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long ( Argyrakopoulou, G; Bontozoglou, N; Kalra, B; Kokkinos, A; Konstantinidou, SK; Kouvari, M; Kumar, A; Kumar, M; Kyriakopoulou, K; Mantzoros, CS; Simati, S; Stefanakis, K, 2023) |
"To evaluate the effects of combining topiramate, bupropion and naltrexone in obesity-induced rats on their weight and subcutaneous adipose tissue." | 4.12 | Effects of topiramate, bupropion and naltrexone isolated or combined on subcutaneous adipose tissue in obese rats. ( Correa, OMT; Doretto-Silva, L; Morreale, S; Nassis, C; Petri, G; Santos, JFRD; Scudeler, MA; Veridiano, JM, 2022) |
" This analysis looked at the add-on of NB to incretins to see if weight loss could occur in patients already stabilized on incretin agents." | 4.02 | Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial. ( Barakat, M; Blavignac, J; Burrows, M; Camacho, F; Christensen, RAG; Gould, E; Kamran, E; Wharton, S; Yin, P, 2021) |
"The recent approval of liraglutide, lorcaserin, naltrexone/bupropion extended-release, and phentermine/topiramate extended-release, brings the number of medications for long-term weight loss to 5 (including orlistat)." | 3.83 | Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management. ( Braverman-Panza, J; Fujioka, K, 2016) |
" Keywords used to obtain relevant articles included obesity and drug, or orlistat, topiramate/phentermine, lorcaserin, bupropion/naltrexone, and liraglutide." | 3.83 | Review of pharmacotherapy options for the management of obesity. ( Bragg, R; Crannage, E, 2016) |
"The significant weight loss observed with combination naltrexone-sustained release (SR) 32 mg and bupropion SR 360 mg (NB32) therapy is thought to be due, in part, to bupropion stimulation of hypothalamic pro-opiomelanocortin (POMC) neurons, and naltrexone blockade of opioid receptor-mediated POMC autoinhibition, but the neurobiological mechanisms are not fully understood." | 3.80 | Effect of combined naltrexone and bupropion therapy on the brain's reactivity to food cues. ( Caparelli, EC; Dunayevich, E; Telang, F; Tomasi, D; Volkow, ND; Wang, GJ; Wang, R, 2014) |
" Lorcaserin (Belviq(®)), phentermine/topiramate combination (Qsymia(®)), and bupropion/naltrexone combination have been demonstrated to be effective for the treatment of obesity, as an adjunct to a reduced-calorie diet and physical activity, although their absolute safety has yet to be established with more widespread use or longer use." | 3.79 | Therapies for obesity and medication-associated weight gain. ( Howland, RH, 2013) |
", with naltrexone) has been explored as an anti-obesity strategy, and is particularly effective when co-administered with dual inhibitors of dopamine and norepinephrine reuptake (e." | 3.79 | Effects of amylin and bupropion/naltrexone on food intake and body weight are interactive in rodent models. ( Athanacio, J; Clapper, JR; D'Souza, L; Griffin, PS; Parkes, DG; Roth, JD; Wittmer, C, 2013) |
"Weight loss is associated with improved quality of life in some, but not all, weight loss trials." | 2.80 | Patient-reported quality of life in a randomized placebo-controlled trial of naltrexone/bupropion for obesity. ( Chen, S; Gilder, K; Greenway, FL; Klassen, P; Kolotkin, RL, 2015) |
" However, they are costly and may have adverse effects in some individuals." | 2.72 | Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? ( Lee, SY; Tak, YJ, 2021) |
"Insulin resistance was also assessed at the end." | 2.71 | Weight gain and cardiovascular risk factors during smoking cessation with bupropion or nicotine. ( Alvarez, F; Botella-Carretero, JI; Cantarero, M; Escobar-Morreale, HF; García, G; Martín, I; Valero, AM; Varela, C, 2004) |
"Obesity is a major cause of type 2 diabetes and may complicate type 1 diabetes." | 2.58 | Medication use for the treatment of diabetes in obese individuals. ( Wilding, JPH, 2018) |
"Obesity is a growing epidemic and a major contributor to the global burden of disease." | 2.52 | Drug treatment of obesity: current status and future prospects. ( Dahiya, N; Kakkar, AK, 2015) |
" Thus, if following the appropriate guidelines according to package labels, the practitioner can feel safe in prescribing these medications." | 2.52 | Safety and tolerability of medications approved for chronic weight management. ( Fujioka, K, 2015) |
"Obesity is a major correlate of cardiovascular disease." | 2.50 | Modern obesity pharmacotherapy: weighing cardiovascular risk and benefit. ( Cunningham, JW; Wiviott, SD, 2014) |
"Over the past decade, treatment for obesity has been limited because of an incomplete understanding of the pathophysiology of obesity, lack of recognition of it as a disease, and limited efficacy of treatment options." | 2.50 | Evolving directions in obesity management. ( Aronne, LJ, 2014) |
" However, in the existing studies PHEN/TPM ER had a superior weight loss profile to lorcaserin but the incidence of adverse effects was lower with lorcaserin." | 2.50 | Tolerability and safety of the new anti-obesity medications. ( Aldhoon-Hainerová, I; Hainer, V, 2014) |
"Obesity is an important causative factor in morbidity, disability and premature death." | 2.49 | A review of late-stage CNS drug candidates for the treatment of obesity. ( Gosden, J; Heal, DJ; Smith, SL, 2013) |
"The prevalence of obesity is rising worldwide, with the U." | 2.48 | Recent advancements in drug treatment of obesity. ( Carter, R; Mouralidarane, A; Oben, J; Ray, S; Soeda, J, 2012) |
"The prevalence of obesity is growing rapidly worldwide, and therefore there is a need for effective treatment strategies." | 2.47 | Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'? ( Hatzitolios, AI; Katsiki, N; Mikhailidis, DP, 2011) |
"Bupropion is a norepinephrine and dopamine uptake inhibitor that has been available for several years for the treatment of depression and aiding smokers to quit." | 2.44 | Bupropion for weight reduction. ( Gadde, KM; Xiong, GL, 2007) |
"Weight gain is cited as a primary reason for not trying to quit smoking." | 2.42 | Smoking cessation and weight gain. ( Fernández Pinilla, MC; Fernández-Cruz, A; Filozof, C, 2004) |
"Measuring nicotine dependence using the Fagerström Test for Nicotine Dependence may help to define the therapeutic strategy." | 2.42 | [Current therapeutic strategies in smoking cessation]. ( Aubin, HJ; Berlin, I; Borgne, A, 2004) |
"Obesity is a complex endocrine disease, mainly caused by environmental, behavioral and biological factors." | 1.62 | [Pharmacotherapy for obesity]. ( Abawi, O; van den Akker, ELT; van der Valk, ES; van der Voorn, B; van Rossum, EFC; Welling, MS, 2021) |
" Central nervous system-active medications have the potential to affect mood; therefore, post hoc analysis of clinical trial data was conducted to evaluate psychiatric adverse events (PAEs) and effects on mood of NB therapy versus placebo." | 1.51 | Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis. ( Acevedo, LM; Apovian, CM; Dunayevich, E; Greenway, FL; McElroy, SL; Pi-Sunyer, X, 2019) |
"Obesity is a chronic disease universally defined as an excess of adipose tissue resulting in body mass index (BMI) > 30." | 1.46 | Obesity Epidemic: Pharmaceutical Weight Loss. ( Curry, SA, 2017) |
"Because obesity can affect catecholaminergic signaling, we determined the effects of i." | 1.34 | Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice. ( Billes, SK; Cowley, MA, 2007) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (0.92) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 23 (21.10) | 29.6817 |
2010's | 73 (66.97) | 24.3611 |
2020's | 12 (11.01) | 2.80 |
Authors | Studies |
---|---|
Roberto da Silva, G | 1 |
Carneiro, MG | 1 |
Barbosa, MP | 1 |
Costa, JA | 1 |
de Souza, IA | 1 |
Dos Santos Oliveira, L | 1 |
de Vasconcelos, DAA | 1 |
do Nascimento, E | 1 |
Matos, RJB | 1 |
Lopes de Souza, S | 1 |
de Freitas, MFL | 1 |
Scudeler, MA | 1 |
Morreale, S | 1 |
Doretto-Silva, L | 1 |
Petri, G | 1 |
Santos, JFRD | 1 |
Nassis, C | 1 |
Correa, OMT | 1 |
Veridiano, JM | 1 |
Grilo, CM | 3 |
Lydecker, JA | 2 |
Fineberg, SK | 1 |
Moreno, JO | 1 |
Ivezaj, V | 1 |
Gueorguieva, R | 2 |
Stefanakis, K | 1 |
Kokkinos, A | 1 |
Argyrakopoulou, G | 1 |
Konstantinidou, SK | 1 |
Simati, S | 1 |
Kouvari, M | 1 |
Kumar, A | 1 |
Kalra, B | 1 |
Kumar, M | 1 |
Bontozoglou, N | 1 |
Kyriakopoulou, K | 1 |
Mantzoros, CS | 1 |
Onakpoya, IJ | 1 |
Lee, JJ | 1 |
Mahtani, KR | 1 |
Aronson, JK | 1 |
Heneghan, CJ | 1 |
Milano, W | 1 |
De Biasio, V | 1 |
Di Munzio, W | 1 |
Foggia, G | 1 |
Capasso, A | 1 |
Barrea, L | 2 |
Pugliese, G | 1 |
Muscogiuri, G | 2 |
Laudisio, D | 1 |
Colao, A | 2 |
Savastano, S | 2 |
Brown, SA | 1 |
Izzy, M | 1 |
Watt, KD | 1 |
Morgan, PT | 1 |
Tak, YJ | 1 |
Lee, SY | 1 |
van Rossum, EFC | 1 |
Welling, MS | 1 |
van der Voorn, B | 1 |
van der Valk, ES | 1 |
Abawi, O | 1 |
van den Akker, ELT | 1 |
Wharton, S | 1 |
Yin, P | 1 |
Burrows, M | 1 |
Gould, E | 1 |
Blavignac, J | 1 |
Christensen, RAG | 1 |
Kamran, E | 1 |
Camacho, F | 1 |
Barakat, M | 1 |
Dalton, M | 1 |
Finlayson, G | 1 |
Walsh, B | 4 |
Halseth, AE | 3 |
Duarte, C | 1 |
Blundell, JE | 1 |
Wilding, JPH | 2 |
Guerdjikova, AI | 2 |
Shan, K | 2 |
Dunayevich, E | 10 |
McElroy, SL | 3 |
Bersoux, S | 1 |
Byun, TH | 1 |
Chaliki, SS | 1 |
Poole, KG | 1 |
Cataldi, M | 1 |
Guida, B | 1 |
Taglialatela, M | 1 |
Pi-Sunyer, X | 1 |
Apovian, CM | 3 |
Acevedo, LM | 1 |
Greenway, FL | 9 |
Bello, NT | 2 |
Chatzis, P | 1 |
Tziomalos, K | 1 |
Pratilas, GC | 1 |
Makris, V | 1 |
Sotiriadis, A | 1 |
Dinas, K | 1 |
Aronne, L | 1 |
Rubino, D | 1 |
Still, C | 1 |
Wyatt, H | 1 |
Burns, C | 3 |
Kim, D | 2 |
Smith, SR | 2 |
Fujioka, K | 12 |
Gupta, AK | 3 |
Billes, SK | 5 |
Howland, RH | 2 |
White, MA | 1 |
Wang, GJ | 1 |
Tomasi, D | 1 |
Volkow, ND | 1 |
Wang, R | 1 |
Telang, F | 1 |
Caparelli, EC | 1 |
Hollander, P | 1 |
Plodkowski, R | 2 |
Greenway, F | 1 |
Bays, H | 1 |
Klassen, P | 2 |
Sinnayah, P | 1 |
Cowley, MA | 4 |
Verpeut, JL | 1 |
Ueno, H | 1 |
Nakazato, M | 1 |
Hainer, V | 2 |
Aldhoon-Hainerová, I | 1 |
Aronne, LJ | 3 |
Cunningham, JW | 1 |
Wiviott, SD | 1 |
Caixàs, A | 1 |
Albert, L | 1 |
Capel, I | 1 |
Rigla, M | 1 |
Citrome, L | 2 |
Rubio, MA | 1 |
Buehler, AM | 1 |
Zimmerman, MP | 1 |
Mehr, SR | 1 |
Kakkar, AK | 1 |
Dahiya, N | 1 |
Mori, N | 1 |
Keck, PE | 1 |
Nau, JY | 1 |
Greig, SL | 1 |
Keating, GM | 1 |
Bragg, R | 1 |
Crannage, E | 1 |
McGinty, EE | 1 |
Baller, J | 1 |
Azrin, ST | 1 |
Juliano-Bult, D | 1 |
Daumit, GL | 1 |
Kolotkin, RL | 1 |
Chen, S | 1 |
Gilder, K | 3 |
Ali, KF | 1 |
Shukla, AP | 1 |
Yang, M | 1 |
Chen, H | 1 |
Johnson, ML | 1 |
Essien, EJ | 1 |
Peters, RJ | 1 |
Wu, IH | 1 |
Abughosh, SM | 1 |
Nuffer, W | 1 |
Trujillo, JM | 1 |
Megyeri, J | 1 |
Sharfstein, JM | 1 |
Psaty, BM | 1 |
Nissen, SE | 1 |
Wolski, KE | 1 |
Prcela, L | 1 |
Wadden, T | 1 |
Buse, JB | 1 |
Bakris, G | 1 |
Perez, A | 1 |
Tolles, J | 1 |
Lewis, RJ | 1 |
Wise, J | 1 |
Alfaris, N | 1 |
Kyle, TK | 1 |
Nadai, J | 1 |
Stanford, FC | 1 |
O'Neil, PM | 3 |
Hong, K | 1 |
Herrmann, K | 1 |
Dybala, C | 1 |
Lam, H | 1 |
Foreyt, JP | 2 |
Braverman-Panza, J | 1 |
Halpern, B | 2 |
Mancini, MC | 1 |
Stefanidis, A | 1 |
Man Lee, CC | 1 |
Brown, WA | 1 |
Oldfield, BJ | 1 |
Halseth, A | 1 |
Igel, LI | 1 |
Kumar, RB | 1 |
Saunders, KH | 1 |
Curry, SA | 1 |
Kapoor, S | 1 |
Whitehouse, MJ | 1 |
Guttadauria, M | 3 |
Anderson, JW | 2 |
Atkinson, RL | 1 |
Gadde, KM | 6 |
O'Neil, P | 1 |
Schumacher, D | 1 |
Smith, D | 1 |
Tollefson, GD | 1 |
Weber, E | 1 |
Plodkowski, RA | 2 |
Nguyen, Q | 1 |
Sundaram, U | 1 |
Nguyen, L | 1 |
Chau, DL | 1 |
St Jeor, S | 1 |
Lee, MW | 1 |
Padwal, R | 1 |
Tollefson, G | 2 |
Erickson, J | 2 |
Wilcox, CS | 1 |
Oskooilar, N | 1 |
Erickson, JS | 2 |
Katz, BB | 1 |
Kaplan, LM | 1 |
Wadden, TA | 2 |
Foster, GD | 1 |
Hill, JO | 1 |
Klein, S | 1 |
Perri, MG | 1 |
Pi-Sunyer, FX | 1 |
Rock, CL | 1 |
Maier, HN | 1 |
Kim, DD | 2 |
Mudaliar, S | 1 |
Astrup, A | 1 |
Katsiki, N | 1 |
Hatzitolios, AI | 1 |
Mikhailidis, DP | 1 |
Faria, AM | 1 |
Halpern, A | 1 |
Bray, GA | 1 |
Ryan, DH | 1 |
Makowski, CT | 1 |
Gwinn, KM | 1 |
Hurren, KM | 1 |
Hiatt, WR | 1 |
Thomas, A | 1 |
Goldfine, AB | 1 |
Heal, DJ | 1 |
Gosden, J | 1 |
Smith, SL | 1 |
Mercer, SL | 1 |
Carter, R | 1 |
Mouralidarane, A | 1 |
Ray, S | 1 |
Soeda, J | 1 |
Oben, J | 1 |
Clapper, JR | 1 |
Athanacio, J | 1 |
Wittmer, C | 1 |
Griffin, PS | 1 |
D'Souza, L | 1 |
Parkes, DG | 1 |
Roth, JD | 1 |
Jain, AK | 1 |
Kaplan, RA | 1 |
Allison, DB | 2 |
Brewer, ER | 1 |
Leadbetter, RA | 1 |
Richard, N | 1 |
Haight, B | 1 |
Jamerson, BD | 1 |
Buaron, KS | 1 |
Metz, A | 1 |
Botella-Carretero, JI | 1 |
Escobar-Morreale, HF | 1 |
Martín, I | 1 |
Valero, AM | 1 |
Alvarez, F | 1 |
García, G | 1 |
Varela, C | 1 |
Cantarero, M | 1 |
Filozof, C | 1 |
Fernández Pinilla, MC | 1 |
Fernández-Cruz, A | 1 |
Shekelle, PG | 1 |
Morton, SC | 1 |
Maglione, M | 1 |
Suttorp, M | 1 |
Tu, W | 1 |
Li, Z | 1 |
Maggard, M | 1 |
Mojica, WA | 1 |
Shugarman, L | 1 |
Solomon, V | 1 |
Borgne, A | 1 |
Aubin, HJ | 1 |
Berlin, I | 1 |
Carter, GT | 1 |
Yudkowsky, MP | 1 |
Han, JJ | 1 |
McCrory, MA | 1 |
Zimmerman, M | 1 |
Posternak, MA | 1 |
Attiullah, N | 1 |
Friedman, M | 1 |
Boland, RJ | 1 |
Baymiller, S | 1 |
Berlowitz, SL | 1 |
Rahman, S | 1 |
Uy, KK | 1 |
Singer, S | 1 |
Chelminski, I | 1 |
Menaster, MJ | 1 |
McCreadie, R | 1 |
Hu, J | 1 |
Redden, DT | 1 |
Berrettini, WH | 1 |
Shields, PG | 1 |
Restine, SL | 1 |
Pinto, A | 1 |
Lerman, C | 1 |
Xiong, GL | 1 |
Ramseier, CA | 1 |
Bornstein, MM | 1 |
Saxer, UP | 1 |
Klingler, K | 1 |
Walter, C | 1 |
Yonish, GM | 1 |
Foust, MS | 1 |
Wagner, HR | 2 |
Aylwin, S | 1 |
Al-Zaman, Y | 1 |
Parker, CB | 1 |
Maner, LG | 1 |
Logue, EJ | 1 |
Drezner, MK | 1 |
Krishnan, KR | 1 |
McKenney, J | 1 |
Nobrega, JN | 1 |
Coscina, DV | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo[NCT02317744] | 22 participants (Actual) | Interventional | 2014-12-31 | Completed | |||
The Use of a Virtual Weight Management Program for Prescription of Phentermine in Patients With Overweight or Obesity Compared to Standard Face to Face Visits[NCT04614545] | Phase 4 | 70 participants (Actual) | Interventional | 2021-01-01 | Completed | ||
A Multicenter, Randomized, Double Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Naltrexone Sustained Release (SR)/Bupropion Sustained Release (SR) and Placebo in Obese Subjects[NCT00567255] | Phase 3 | 1,496 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
Placebo-Controlled Trial of Bupropion for the Treatment of Binge Eating Disorder[NCT00414167] | Phase 2/Phase 3 | 61 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
Naltrexone Sustained Release (SR) 32 mg and Bupropion Sustained Release (SR) 360 mg Combination Therapy in Functional Magnetic Resonance Imaging (fMRI) Changes in Overweight or Obese Subjects[NCT00711477] | Phase 2 | 46 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
A Multicenter, Randomized, Double Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Naltrexone 32 mg Sustained Release (SR)/Bupropion 360 mg Sustained Release (SR) and Placebo in Obese Subjects With Type 2 Diabetes Mellitus[NCT00474630] | Phase 3 | 505 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events (MACE) in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR/Bupropion SR[NCT01601704] | Phase 3 | 8,910 participants (Actual) | Interventional | 2012-06-30 | Terminated | ||
A Multicenter, Randomized, Open-Label, Controlled, Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects (The Ignite Study)[NCT01764386] | Phase 3 | 242 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
Phase II Randomized, Double-Blind Trial of Bupropion Versus Bupropion + Naltrexone for Smoking Cessation[NCT00419731] | Phase 2/Phase 3 | 120 participants (Anticipated) | Interventional | 2006-11-30 | Recruiting | ||
The Beef WISE Study: Beef's Role in Weight Improvement, Satisfaction, and Energy[NCT02627105] | 120 participants (Actual) | Interventional | 2015-09-30 | Completed | |||
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of Naltrexone Sustained Release (SR)/Bupropion SR and Placebo in Subjects With Obesity Participating in a Behavior Modification Program[NCT00456521] | Phase 3 | 793 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
A Multicenter, Randomized, Double Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Two Doses of Naltrexone Sustained Release (SR)/Bupropion Sustained Release (SR) and Placebo in Obese Subjects[NCT00532779] | Phase 3 | 1,742 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
Effect of Sulphate-bicarbonate-calcium Water Consumption on the Body Weight and Gut Microbiota Composition in Overweight and Obese Patients Under Low-calorie Diet[NCT02154230] | 0 participants (Actual) | Interventional | 2013-11-30 | Withdrawn (stopped due to failure to enroll) | |||
WhatsApp Embedded in Routine Service Delivery for Smoking Cessation: Effects on Success Rates in a Randomized Controlled Study[NCT03714971] | 127 participants (Actual) | Interventional | 2017-03-01 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Binge eating will be assessed by interview and self-report and the primary outcome is frequency. Frequency also is defined continuously (analyzed dimensionally). (NCT02317744)
Timeframe: 6 month follow-up (an average of 6 months following treatment)
Intervention | binge eating days (out of 28) (Mean) |
---|---|
Naltrexone/ Bupropion Combination | 5.4 |
Pill Placebo | 2.9 |
Binge eating will be assessed by interview and self-report and the primary outcome is frequency. Frequency also is defined continuously (analyzed dimensionally). (NCT02317744)
Timeframe: Post-treatment (at 3 months)
Intervention | binge eating days (out of 28) (Mean) |
---|---|
Naltrexone/ Bupropion Combination | 4.4 |
Pill Placebo | 3.0 |
BMI is calculated using measured height and weight. (NCT02317744)
Timeframe: 6 month follow-up (an average of 6 months following treatment)
Intervention | kg/m^2 (Mean) |
---|---|
Naltrexone/ Bupropion Combination | 35.9 |
Pill Placebo | 40.3 |
BMI is calculated using measured height and weight. (NCT02317744)
Timeframe: Post-treatment (at 3 months)
Intervention | kg/m^2 (Mean) |
---|---|
Naltrexone/ Bupropion Combination | 34.5 |
Pill Placebo | 39.7 |
Percentage of patients that took the medication as prescribed (NCT04614545)
Timeframe: 12 weeks
Intervention | Percentage of pts completed medication (Number) |
---|---|
Virtual Visits | 93.3 |
Face to Face Visits | 83.3 |
Assessed as percentage of patients who completed all visits (NCT04614545)
Timeframe: 12 weeks
Intervention | Percentage of completed patients (Number) |
---|---|
Virtual Visits | 82.9 |
Face to Face Visits | 62.9 |
The primary endpoint is mean change in body weight (%) from baseline (visit 1) to 12 weeks (visit 4) in body weight. (NCT04614545)
Timeframe: 12 weeks
Intervention | mean change in body weight (%) (Mean) |
---|---|
Virtual Visits | -6.61 |
Face to Face Visits | -7.68 |
(NCT04614545)
Timeframe: 12 weeks
Intervention | Percentage of patients on full dose (Number) |
---|---|
Virtual Visits | 85.7 |
Face to Face Visits | 90 |
(NCT04614545)
Timeframe: 12 weeks
Intervention | Percentage of patients with >5% wt loss (Number) |
---|---|
Virtual Visits | 64.7 |
Face to Face Visits | 70.5 |
"Beginning at Week 28 through Week 44, NB32-treated subjects who failed to achieve or maintain at least 5% body weight loss from baseline were re-randomized (1:1 ratio) to continue NB32 or begin treatment with a higher dose of naltrexone SR - naltrexone SR 48 mg/bupropion SR 360 mg (referred to as NB48) (daily dose of bupropion SR was 360 mg for NB32 and NB48).The analysis of NB32 vs. placebo at Week 56 was completed using a weighted analysis. This analysis was referred to as the weighted LOCF analysis.~Subjects treated with NB32 who were re-randomized to NB48 were not included. Subjects re-randomized to NB32 were double-weighted and subjects who were not re-randomized were single-weighted. Subjects in the placebo group were single-weighted. The double weighting analysis restored the influence of poor performers at Weeks 28 to 44 in the NB32 group without including any data from the higher dose group (NB48)." (NCT00567255)
Timeframe: Baseline, 56 weeks
Intervention | percentage of body weight (Least Squares Mean) |
---|---|
NB32 | -6.40 |
Placebo | -1.23 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
Intervention | percentage of participants (Number) |
---|---|
NB32 | 27.27 |
Placebo | 7.02 |
"Beginning at Week 28 through Week 44, NB32-treated subjects who failed to achieve or maintain at least 5% body weight loss from baseline were re-randomized (1:1 ratio) to continue NB32 or begin treatment with a higher dose of naltrexone SR - naltrexone SR 48 mg/bupropion SR 360 mg (referred to as NB48) (daily dose of bupropion SR was 360 mg for NB32 and NB48).The analysis of NB32 vs. placebo at Week 56 was completed using a weighted analysis. This analysis was referred to as the weighted LOCF analysis.~Subjects treated with NB32 who were re-randomized to NB48 were not included. Subjects re-randomized to NB32 were double-weighted and subjects who were not re-randomized were single-weighted. Subjects in the placebo group were single-weighted. The double weighting analysis restored the influence of poor performers at Weeks 28 to 44 in the NB32 group without including any data from the higher dose group (NB48)." (NCT00567255)
Timeframe: Baseline, 56 weeks
Intervention | percentage of participants (Number) |
---|---|
NB32 | 50.48 |
Placebo | 17.11 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
Intervention | mm Hg (Least Squares Mean) |
---|---|
NB32 | 0.20 |
Placebo | -0.67 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
Intervention | mg/dL (Least Squares Mean) |
---|---|
NB32 | -2.11 |
Placebo | -1.73 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
Intervention | mg/dL (Least Squares Mean) |
---|---|
NB32 | 1.19 |
Placebo | -1.40 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
Intervention | percent change (Least Squares Mean) |
---|---|
NB32 | -14.14 |
Placebo | -0.50 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
Intervention | mg/dL (Least Squares Mean) |
---|---|
NB32 | -4.36 |
Placebo | 0.00 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
Intervention | percent change (Least Squares Mean) |
---|---|
NB32 | -7.32 |
Placebo | -1.36 |
The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00567255)
Timeframe: Baseline, 28 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | -2.68 |
Placebo | -2.20 |
The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00567255)
Timeframe: Baseline, 28 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | -3.20 |
Placebo | -3.18 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
Intervention | percent change (Least Squares Mean) |
---|---|
NB32 | -9.38 |
Placebo | -1.14 |
HOMA-IR= Homeostasis Model Assessment-Insulin Resistance (NCT00567255)
Timeframe: Baseline, 28 weeks
Intervention | percent change (Least Squares Mean) |
---|---|
NB32 | -16.44 |
Placebo | -4.15 |
IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression. (NCT00567255)
Timeframe: Baseline, 28 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | -0.23 |
Placebo | -0.28 |
IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment (NCT00567255)
Timeframe: Baseline, 28 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | 9.94 |
Placebo | 6.17 |
Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult (NCT00567255)
Timeframe: Baseline, 28 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | -18.32 |
Placebo | -11.09 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
Intervention | mm Hg (Least Squares Mean) |
---|---|
NB32 | -0.93 |
Placebo | -1.23 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
Intervention | cm (Least Squares Mean) |
---|---|
NB32 | -6.16 |
Placebo | -2.74 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
Intervention | percentage of body weight (Least Squares Mean) |
---|---|
NB32 | -6.45 |
Placebo | -1.89 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
Intervention | percentage of participants (Number) |
---|---|
NB32 | 55.64 |
Placebo | 17.54 |
(NCT00414167)
Timeframe: One week (at post treatment)
Intervention | episodes/week (Mean) |
---|---|
Bupropion | 0.8 |
Placebo | 1.0 |
Percent loss in Body Mass Index (NCT00414167)
Timeframe: 8 weeks (baseline and 8 weeks)
Intervention | Percent loss (Mean) |
---|---|
Bupropion | 1.8 |
Placebo | 0.6 |
Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult (NCT00711477)
Timeframe: Baseline, 4 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | -13.55 |
Placebo | -4.14 |
The Dutch Eating Behavior Questionnaire is a 33-item self-report measure designed to assess the type of eating behavior and is organized into 3 subscales (emotional eating, externally-induced eating, and restrained eating). Subjects rated the frequency of their eating behaviors using a 5-point scale, where 1=never, 2=seldom, 3=sometimes, 4=often, and 5=very often. The Emotional Eating A subscale (clearly labeled emotions) consisted of 9 items and the scores ranged from 9 (better outcome) to 45 (worse outcome). (NCT00711477)
Timeframe: Baseline, 4 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | -1.16 |
Placebo | 0.48 |
The Dutch Eating Behavior Questionnaire is a 33-item self-report measure designed to assess the type of eating behavior and is organized into 3 subscales (emotional eating, externally-induced eating, and restrained eating). Subjects rated the frequency of their eating behaviors using a 5-point scale, where 1=never, 2=seldom, 3=sometimes, 4=often, and 5=very often. The Emotional Eating B subscale (diffuse emotions) consisted of 4 items and the scores ranged from 4 (better outcome) to 20 (worse outcome). (NCT00711477)
Timeframe: Baseline, 4 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | -0.90 |
Placebo | 0.45 |
The Dutch Eating Behavior Questionnaire is a 33-item self-report measure designed to assess the type of eating behavior and is organized into 3 subscales (emotional eating, externally-induced eating, and restrained eating). Subjects rated the frequency of their eating behaviors using a 5-point scale where 1=never, 2=seldom, 3=sometimes, 4=often, and 5=very often. The External Eating subscale consisted of 10 items and the scores ranged from 10 (better outcome) to 50 (worse outcome). (NCT00711477)
Timeframe: Baseline, 4 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | -2.64 |
Placebo | -0.16 |
The Dutch Eating Behavior Questionnaire is a 33-item self-report measure designed to assess the type of eating behavior and is organized into 3 subscales (emotional eating, externally-induced eating, and restrained eating). Subjects rated the frequency of their eating behaviors using a 5-point scale, where 1=never, 2=seldom, 3=sometimes, 4=often, and 5=very often. The Restrained Eating subscale consisted of 10 items and the scores ranged from 10 (worse outcome) to 50 (better outcome). (NCT00711477)
Timeframe: Baseline, 4 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | 1.47 |
Placebo | 1.87 |
(NCT00711477)
Timeframe: Baseline, 4 weeks
Intervention | percentage of body weight (Least Squares Mean) |
---|---|
NB32 | -0.99 |
Placebo | -0.43 |
Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo. (NCT00711477)
Timeframe: Baseline, 4 weeks
Intervention | percent activation (Mean) |
---|---|
Placebo | -0.42 |
NB32 | 0.16 |
Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo. (NCT00711477)
Timeframe: Baseline, 4 weeks
Intervention | percent activation (Mean) |
---|---|
Placebo | -0.16 |
NB32 | 0.60 |
Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo. (NCT00711477)
Timeframe: Baseline, 4 weeks
Intervention | percent activation (Mean) |
---|---|
Placebo | -0.79 |
NB32 | 0.21 |
Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo. (NCT00711477)
Timeframe: Baseline, 4 weeks
Intervention | percent activation (Mean) |
---|---|
Placebo | -0.16 |
NB32 | 0.30 |
Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo. (NCT00711477)
Timeframe: Baseline, 4 weeks
Intervention | percent activation (Mean) |
---|---|
Placebo | -0.35 |
NB32 | 0.34 |
Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo. (NCT00711477)
Timeframe: Baseline, 4 weeks
Intervention | percent activation (Mean) |
---|---|
Placebo | -0.56 |
NB32 | 0.74 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | percentage of participants (Number) |
---|---|
NB32 | 18.49 |
Placebo | 5.66 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | mm Hg (Least Squares Mean) |
---|---|
NB32 | -1.06 |
Placebo | -1.47 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | mg/dL (Least Squares Mean) |
---|---|
NB32 | -11.87 |
Placebo | -4.02 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | mg/dL (Least Squares Mean) |
---|---|
NB32 | 3.03 |
Placebo | -0.29 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | percent change (Least Squares Mean) |
---|---|
NB32 | -13.48 |
Placebo | -10.35 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | mg/dL (Least Squares Mean) |
---|---|
NB32 | -1.44 |
Placebo | -0.01 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | percent change (Least Squares Mean) |
---|---|
NB32 | -11.20 |
Placebo | -0.80 |
The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | -1.48 |
Placebo | -1.52 |
The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | -1.97 |
Placebo | -2.40 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | percent (Least Squares Mean) |
---|---|
NB32 | -0.63 |
Placebo | -0.14 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | percent change (Least Squares Mean) |
---|---|
NB32 | -20.91 |
Placebo | -13.29 |
HOMA-IR= Homeostasis Model Assessment-Insulin Resistance (NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | percent change (Least Squares Mean) |
---|---|
NB32 | -20.56 |
Placebo | -14.67 |
IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression. (NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | 0.01 |
Placebo | -1.60 |
IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment (NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | 9.27 |
Placebo | 7.90 |
Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult (NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | -11.89 |
Placebo | -6.91 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | mm Hg (Least Squares Mean) |
---|---|
NB32 | 0.03 |
Placebo | -1.12 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | cm (Least Squares Mean) |
---|---|
NB32 | -4.97 |
Placebo | -2.89 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | percentage of body weight (Least Squares Mean) |
---|---|
NB32 | -5.03 |
Placebo | -1.75 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | percentage of participants (Number) |
---|---|
NB32 | 44.53 |
Placebo | 18.87 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | percentage of participants (Number) |
---|---|
NB32 | 20.72 |
Placebo | 10.22 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | percentage of participants (Number) |
---|---|
NB32 | 44.14 |
Placebo | 26.28 |
Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed. Odds ratio not calculated as there were no subjects in the NB32 group that discontinued due to poor glycemic control. (NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | percentage of participants (Number) |
---|---|
NB32 | 0 |
Placebo | 1.89 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | percentage of participants (Number) |
---|---|
NB32 | 22.26 |
Placebo | 35.22 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | percentage of participants (Number) |
---|---|
NB32 | 3.02 |
Placebo | 1.26 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | percentage of participants (Number) |
---|---|
NB32 | 1.89 |
Placebo | 1.26 |
Due to early termination of the study, the pre-planned 50% interim analysis is considered the primary analysis for outcome measures. (NCT01601704)
Timeframe: Confirmed occurrence of event between Day 1 (randomization) and up to a maximum of 4 years of follow-up
Intervention | Participants (Count of Participants) |
---|---|
NB32 | 17 |
Placebo | 34 |
Due to early termination of the study, the pre-planned 50% interim analysis is considered the primary analysis for outcome measures. (NCT01601704)
Timeframe: Confirmed occurrence of event between Day 1 (randomization) and up to a maximum of 4 years of follow-up
Intervention | Participants (Count of Participants) |
---|---|
NB32 | 133 |
Placebo | 142 |
The primary endpoint is the time from randomization to the first confirmed occurrence of any event within the primary MACE composite (defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke). Due to early termination of the study, pre-planned 50% interim analysis is considered the primary analysis for outcome measures. The pre-planned 50% interim analysis was conducted when 50% of the total planned MACE were observed. (NCT01601704)
Timeframe: Confirmed occurrence of event between Day 1 (randomization) and up to a maximum of 4 years of follow-up
Intervention | Participants (Count of Participants) |
---|---|
NB32 | 90 |
Placebo | 102 |
Due to early termination of the study, the pre-planned 50% interim analysis is considered the primary analysis for outcome measures. (NCT01601704)
Timeframe: Confirmed occurrence of event between Day 1 (randomization) and up to a maximum of 4 years of follow-up
Intervention | Participants (Count of Participants) |
---|---|
NB32 | 55 |
Placebo | 57 |
Due to early termination of the study, the pre-planned 50% interim analysis is considered the primary analysis for outcome measures. (NCT01601704)
Timeframe: Confirmed occurrence of event between Day 1 (randomization) and up to a maximum of 4 years of follow-up
Intervention | Participants (Count of Participants) |
---|---|
NB32 | 22 |
Placebo | 21 |
(NCT01764386)
Timeframe: Baseline to Week 26
Intervention | kg (Least Squares Mean) |
---|---|
NB + CLI | -9.7 |
Usual Care | -1.0 |
(NCT01764386)
Timeframe: Baseline to Week 26
Intervention | uIU/mL (Least Squares Mean) |
---|---|
NB + CLI | -7.5 |
Usual Care | -3.4 |
(NCT01764386)
Timeframe: Baseline to Week 26
Intervention | mm Hg (Least Squares Mean) |
---|---|
NB + CLI | -1.7 |
Usual Care | -1.3 |
(NCT01764386)
Timeframe: Baseline to Week 26
Intervention | mg/dL (Least Squares Mean) |
---|---|
NB + CLI | 4.1 |
Usual Care | 0.1 |
(NCT01764386)
Timeframe: Baseline to Week 26
Intervention | mg/dL (Least Squares Mean) |
---|---|
NB + CLI | -2.0 |
Usual Care | -1.9 |
(NCT01764386)
Timeframe: Baseline to Week 26
Intervention | mg/dL (Least Squares Mean) |
---|---|
NB + CLI | -2.9 |
Usual Care | 1.6 |
(NCT01764386)
Timeframe: Baseline to Week 26
Intervention | mg/dL (Least Squares Mean) |
---|---|
NB + CLI | -13.6 |
Usual Care | 2.8 |
(NCT01764386)
Timeframe: Baseline to Week 26
Intervention | bpm (Least Squares Mean) |
---|---|
NB + CLI | 1.7 |
Usual Care | -0.3 |
HOMA-IR is an insulin sensitivity index that is calculated as HOMA-IR = (Glucose * Insulin) / 405, where glucose is in mass units (mg/dL) and insulin is in µIU/mL. Higher values indicate lower insulin sensitivity. (NCT01764386)
Timeframe: Baseline to Week 26
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB + CLI | -2.0 |
Usual Care | -0.8 |
Arizona Sexual Experiences (ASEX) scale is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Possible total scores range from 5 to 30, with the higher scores indicating more sexual dysfunction. (NCT01764386)
Timeframe: Baseline to Week 26
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB + CLI | -2.2 |
Usual Care | -0.1 |
The BES is a 16-item questionnaire that identifies different levels of binge-eating severity, with total scores ranging between 0-46. BES scores were categorized as follows: None = Scores ≤17 indicated no significant binge eating, Moderate = scores from 18 to 26 (inclusive), Severe = scores ≥27 indicated severe levels of binge eating. (NCT01764386)
Timeframe: Baseline to Week 26
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB + CLI | -6.8 |
Usual Care | 1.1 |
Impact of Weight on Quality of Life-Lite Questionnaire (IWQOL-Lite) is a self-reported assessment of perceived effect of weight on quality of life. It consists of 31 items organized in 5 domains (physical function, self-esteem, sexual life, public distress and work). IWQOL-Lite total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment. (NCT01764386)
Timeframe: Baseline to Week 26
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB + CLI | 16.4 |
Usual Care | -1.0 |
(NCT01764386)
Timeframe: Baseline to Week 26
Intervention | mm Hg (Least Squares Mean) |
---|---|
NB + CLI | -4.8 |
Usual Care | -2.8 |
(NCT01764386)
Timeframe: Baseline to Week 26
Intervention | cm (Least Squares Mean) |
---|---|
NB + CLI | -6.96 |
Usual Care | -1.64 |
(NCT01764386)
Timeframe: Baseline to Week 26
Intervention | percent change in body weight (Least Squares Mean) |
---|---|
NB + CLI | -9.46 |
Usual Care | -0.94 |
(NCT01764386)
Timeframe: Baseline to Week 26
Intervention | percentage of participants (Number) |
---|---|
NB + CLI | 42.3 |
Usual Care | 3.7 |
(NCT01764386)
Timeframe: Baseline to Week 26
Intervention | percentage of participants (Number) |
---|---|
NB + CLI | 12.7 |
Usual Care | 0.0 |
(NCT01764386)
Timeframe: Baseline to Week 26
Intervention | percentage of participants (Number) |
---|---|
NB + CLI | 84.5 |
Usual Care | 12.2 |
(NCT00456521)
Timeframe: Baseline, 56 weeks
Intervention | percentage of participants (Number) |
---|---|
NB32 | 41.49 |
Placebo | 20.21 |
(NCT00456521)
Timeframe: Baseline, 56 weeks
Intervention | mmHg (Least Squares Mean) |
---|---|
NB32 | -1.41 |
Placebo | -2.78 |
(NCT00456521)
Timeframe: Baseline, 56 weeks
Intervention | mg/dL (Least Squares Mean) |
---|---|
NB32 | -2.36 |
Placebo | -1.08 |
(NCT00456521)
Timeframe: Baseline, 56 weeks
Intervention | mg/dL (Least Squares Mean) |
---|---|
NB32 | 4.10 |
Placebo | 0.87 |
(NCT00456521)
Timeframe: Baseline, 56 weeks
Intervention | percent change (Least Squares Mean) |
---|---|
NB32 | -27.98 |
Placebo | -15.45 |
(NCT00456521)
Timeframe: Baseline, 56 weeks
Intervention | mg/dL (Least Squares Mean) |
---|---|
NB32 | 5.43 |
Placebo | 8.13 |
(NCT00456521)
Timeframe: Baseline, 56 weeks
Intervention | percent change (Least Squares Mean) |
---|---|
NB32 | -16.62 |
Placebo | -8.51 |
The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00456521)
Timeframe: Baseline, 56 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | -2.06 |
Placebo | -1.97 |
The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00456521)
Timeframe: Baseline, 56 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | -2.54 |
Placebo | -2.43 |
(NCT00456521)
Timeframe: Baseline, 56 weeks
Intervention | percent change (Least Squares Mean) |
---|---|
NB32 | -25.87 |
Placebo | -16.89 |
HOMA-IR= Homeostasis Model Assessment-Insulin Resistance (NCT00456521)
Timeframe: Baseline, 56 weeks
Intervention | percent change (Least Squares Mean) |
---|---|
NB32 | -29.93 |
Placebo | -16.56 |
IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression. (NCT00456521)
Timeframe: Baseline, 56 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | 0.09 |
Placebo | -0.00 |
IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment (NCT00456521)
Timeframe: Baseline, 56 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | 13.43 |
Placebo | 10.29 |
Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult (NCT00456521)
Timeframe: Baseline, 56 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | -13.75 |
Placebo | -8.46 |
(NCT00456521)
Timeframe: Baseline, 56 weeks
Intervention | mmHg (Least Squares Mean) |
---|---|
NB32 | -1.32 |
Placebo | -3.87 |
(NCT00456521)
Timeframe: Baseline, 56 weeks
Intervention | cm (Least Squares Mean) |
---|---|
NB32 | -9.98 |
Placebo | -6.77 |
(NCT00456521)
Timeframe: Baseline, 56 weeks
Intervention | percentage of body weight (Least Squares Mean) |
---|---|
NB32 | -9.29 |
Placebo | -5.08 |
(NCT00456521)
Timeframe: Baseline, 56 weeks
Intervention | percentage of participants (Number) |
---|---|
NB32 | 66.39 |
Placebo | 42.49 |
(NCT00532779)
Timeframe: Baseline, 56 weeks
Intervention | Percentage of participants (Number) |
---|---|
NB16 | 20.17 |
NB32 | 24.63 |
Placebo | 7.44 |
(NCT00532779)
Timeframe: Baseline, 56 weeks
Intervention | mm Hg (Least Squares Mean) |
---|---|
NB16 | 0.09 |
NB32 | 0.04 |
Placebo | -0.86 |
(NCT00532779)
Timeframe: Baseline, 56 weeks
Intervention | mg/dL (Least Squares Mean) |
---|---|
NB16 | -2.39 |
NB32 | -3.24 |
Placebo | -1.30 |
(NCT00532779)
Timeframe: Baseline, 56 weeks
Intervention | mg/dL (Least Squares Mean) |
---|---|
NB16 | 3.36 |
NB32 | 3.42 |
Placebo | -0.06 |
(NCT00532779)
Timeframe: Baseline, 56 weeks
Intervention | percent change (Least Squares Mean) |
---|---|
NB16 | -11.84 |
NB32 | -17.14 |
Placebo | -4.57 |
(NCT00532779)
Timeframe: Baseline, 56 weeks
Intervention | mg/dL (Least Squares Mean) |
---|---|
NB16 | -3.67 |
NB32 | -4.41 |
Placebo | -3.28 |
(NCT00532779)
Timeframe: Baseline, 56 weeks
Intervention | percent change (Least Squares Mean) |
---|---|
NB16 | -7.96 |
NB32 | -12.69 |
Placebo | -3.08 |
The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00532779)
Timeframe: Baseline, 56 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB16 | -1.85 |
NB32 | -2.11 |
Placebo | -1.84 |
The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00532779)
Timeframe: Baseline, 56 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB16 | -2.08 |
NB32 | -2.62 |
Placebo | -2.77 |
(NCT00532779)
Timeframe: Baseline, 56 weeks
Intervention | percent change (Least Squares Mean) |
---|---|
NB16 | -28.02 |
NB32 | -28.98 |
Placebo | -16.66 |
HOMA-IR= Homeostasis Model Assessment-Insulin Resistance (NCT00532779)
Timeframe: Baseline, 56 weeks
Intervention | percent change (Least Squares Mean) |
---|---|
NB16 | -14.33 |
NB32 | -20.19 |
Placebo | -5.90 |
IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression. (NCT00532779)
Timeframe: Baseline, 56 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB16 | 0.02 |
NB32 | -0.27 |
Placebo | -0.72 |
IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment (NCT00532779)
Timeframe: Baseline, 56 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB16 | 11.68 |
NB32 | 12.69 |
Placebo | 8.55 |
Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult (NCT00532779)
Timeframe: Baseline, 56 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB16 | -12.49 |
NB32 | -14.52 |
Placebo | -8.68 |
(NCT00532779)
Timeframe: Baseline, 56 weeks
Intervention | mm Hg (Least Squares Mean) |
---|---|
NB16 | 0.29 |
NB32 | -0.11 |
Placebo | -1.94 |
(NCT00532779)
Timeframe: Baseline, 56 weeks
Intervention | cm (Least Squares Mean) |
---|---|
NB16 | -5.04 |
NB32 | -6.24 |
Placebo | -2.46 |
(NCT00532779)
Timeframe: Baseline, 56 weeks
Intervention | percentage of body weight (Least Squares Mean) |
---|---|
NB16 | -5.00 |
NB32 | -6.14 |
Placebo | -1.33 |
(NCT00532779)
Timeframe: Baseline, 56 weeks
Intervention | percentage of participants (Number) |
---|---|
NB16 | 39.49 |
NB32 | 47.98 |
Placebo | 16.44 |
46 reviews available for bupropion and Obesity
Article | Year |
---|---|
Naltrexone-bupropion (Mysimba) in management of obesity: A systematic review and meta-analysis of unpublished clinical study reports.
Topics: Bupropion; Drug Combinations; Humans; Naltrexone; Obesity | 2020 |
Obesity: The New Global Epidemic Pharmacological Treatment, Opportunities and Limits for Personalized Therapy.
Topics: Anti-Obesity Agents; Bupropion; Epidemics; Global Health; Humans; Liraglutide; Naltrexone; Obesity; | 2020 |
New-generation anti-obesity drugs: naltrexone/bupropion and liraglutide. An update for endocrinologists and nutritionists.
Topics: Anti-Obesity Agents; Bupropion; Drug Combinations; Endocrinology; Humans; Liraglutide; Naltrexone; N | 2020 |
Pharmacotherapy for Weight Loss in Cirrhosis and Liver Transplantation: Translating the Data and Underused Potential.
Topics: Anti-Obesity Agents; Bupropion; Drug Therapy, Combination; Humans; Liraglutide; Liver Cirrhosis; Liv | 2021 |
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Topics: Animals; Anti-Obesity Agents; Benzazepines; Bupropion; Humans; Liraglutide; Naltrexone; Obesity; Orl | 2021 |
Medication use for the treatment of diabetes in obese individuals.
Topics: Animals; Benzazepines; Bupropion; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Humans; Lacton | 2018 |
Pharmacotherapy for obesity: What you need to know.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Benzazepines; Bupropion; Drug Combinations; Humans | 2017 |
Gender-related issues in the pharmacology of new anti-obesity drugs.
Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Dose-Response Relationship, Drug; Drug Combinations; F | 2019 |
The Role of Antiobesity Agents in the Management of Polycystic Ovary Syndrome.
Topics: Androgens; Anti-Obesity Agents; Bupropion; Drug Combinations; Female; Humans; Insulin Resistance; Li | 2018 |
Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Drug Therapy, Combination; Energy Metabolism; H | 2014 |
Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
Topics: Animals; Anti-Obesity Agents; Bupropion; Delayed-Action Preparations; Drug Combinations; Humans; Nal | 2014 |
[Cutting-edge of medicine; the prospects of novel anti-obesity drugs].
Topics: Anti-Obesity Agents; Appetite; Appetite Depressants; Benzazepines; Benzoxazines; Bupropion; Clinical | 2014 |
Tolerability and safety of the new anti-obesity medications.
Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Chemistry, Pharmaceutical; Drug-Related | 2014 |
Overview of new antiobesity drugs.
Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Drug Combinations; Fructose; Glucagon-Li | 2014 |
Evolving directions in obesity management.
Topics: Anti-Obesity Agents; Bupropion; Dopamine Uptake Inhibitors; Forecasting; Glucagon-Like Peptide 1; Gl | 2014 |
Modern obesity pharmacotherapy: weighing cardiovascular risk and benefit.
Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Cardiovascular Diseases; Clinical Trials as Topic; Dru | 2014 |
Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date.
Topics: Anti-Obesity Agents; Bupropion; Drug Combinations; Humans; Naltrexone; Obesity | 2014 |
Drug treatment of obesity: current status and future prospects.
Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Drug Combinations; Drug Therapy, Combination; Fructose | 2015 |
Psychopharmacologic treatment of eating disorders: emerging findings.
Topics: Administration, Intranasal; Anorexia Nervosa; Anti-Obesity Agents; Antidepressive Agents, Second-Gen | 2015 |
Safety and tolerability of medications approved for chronic weight management.
Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Delayed-Action Preparations; Drug-Related Side Effects | 2015 |
Current and emerging medications for overweight or obesity in people with comorbidities.
Topics: Anti-Obesity Agents; Bupropion; Cinnamates; Comorbidity; Cyclohexanes; Diabetes Mellitus; Dyslipidem | 2015 |
Melatonin, Liraglutide, and Naltrexone/Bupropion for the Treatment of Obesity and Medication-Related Weight Gain.
Topics: Anti-Obesity Agents; Bupropion; Drug Combinations; Humans; Liraglutide; Melatonin; Naltrexone; Obesi | 2015 |
Naltrexone ER/Bupropion ER: A Review in Obesity Management.
Topics: Adult; Animals; Anti-Obesity Agents; Bupropion; Delayed-Action Preparations; Drug Combinations; Huma | 2015 |
Interventions to Address Medical Conditions and Health-Risk Behaviors Among Persons With Serious Mental Illness: A Comprehensive Review.
Topics: Behavior Therapy; Bipolar Disorder; Bupropion; Cardiovascular Diseases; Diabetes Mellitus; Dopamine | 2016 |
Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity.
Topics: Animals; Anti-Obesity Agents; Bupropion; Delayed-Action Preparations; Drug Approval; Drug Combinatio | 2016 |
Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes.
Topics: Adult; Anti-Obesity Agents; Bupropion; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Naltrex | 2016 |
A Comparison of New Pharmacological Agents for the Treatment of Obesity.
Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Clinical Trials, Phase III as Topic; Drug Combinations | 2016 |
Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release.
Topics: Animals; Anti-Obesity Agents; Bupropion; Delayed-Action Preparations; Drug Combinations; Fructose; H | 2017 |
Practical Use of Pharmacotherapy for Obesity.
Topics: Androgens; Anti-Obesity Agents; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents | 2017 |
Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity.
Topics: Animals; Bupropion; Chemistry, Pharmaceutical; Clinical Trials, Phase III as Topic; Drug Therapy, Co | 2009 |
Naltrexone for the treatment of obesity: review and update.
Topics: Animals; Bupropion; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Feeding Behavior; Humans; | 2009 |
Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity.
Topics: Administration, Oral; Animals; Appetite; Bupropion; Controlled Clinical Trials as Topic; Delayed-Act | 2009 |
Pharmacologic therapies for obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Benzazepines; Bupropion; Cyclobutanes; | 2010 |
Naltrexone/bupropion: Contrave(R); naltrexone SR/bupropion SR.
Topics: Animals; Anti-Obesity Agents; Bupropion; Clinical Trials, Phase II as Topic; Clinical Trials, Phase | 2010 |
Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'?
Topics: Bupropion; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Diabetes Mellitus, Type | 2011 |
Combination therapy with naltrexone and bupropion for obesity.
Topics: Animals; Bupropion; Dopamine Uptake Inhibitors; Drug Combinations; Humans; Naltrexone; Narcotic Anta | 2011 |
Naltrexone/bupropion: an investigational combination for weight loss and maintenance.
Topics: Anti-Obesity Agents; Bupropion; Diabetes Mellitus; Drug Therapy, Combination; Glycated Hemoglobin; H | 2011 |
A review of late-stage CNS drug candidates for the treatment of obesity.
Topics: Anti-Obesity Agents; Bupropion; Central Nervous System Stimulants; Drug Administration Schedule; Dru | 2013 |
ACS chemical neuroscience molecule spotlight on contrave.
Topics: Anti-Obesity Agents; Bupropion; Clinical Trials, Phase III as Topic; Double-Blind Method; Drug Appro | 2011 |
Recent advancements in drug treatment of obesity.
Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Clinical Trials as Topic; Drug Combinati | 2012 |
Smoking cessation and weight gain.
Topics: Body Composition; Bupropion; Cardiovascular Diseases; Dopamine Uptake Inhibitors; Female; Humans; In | 2004 |
Pharmacological and surgical treatment of obesity.
Topics: Adult; Appetite Depressants; Bupropion; Cyclobutanes; Diethylpropion; Fluoxetine; Fructose; Gastric | 2004 |
[Current therapeutic strategies in smoking cessation].
Topics: Administration, Cutaneous; Bupropion; Chewing Gum; Cognitive Behavioral Therapy; Dopamine Uptake Inh | 2004 |
Why isn't bupropion the most frequently prescribed antidepressant?
Topics: Adult; Ambulatory Care; Antidepressive Agents; Antidepressive Agents, Second-Generation; Bupropion; | 2005 |
Bupropion for weight reduction.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Clinical Trials as Topic; Dose-Response Relatio | 2007 |
Emerging concepts in the medical and surgical treatment of obesity.
Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Baria | 2008 |
21 trials available for bupropion and Obesity
Article | Year |
---|---|
Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial.
Topics: Behavior Therapy; Binge-Eating Disorder; Bupropion; Double-Blind Method; Female; Humans; Male; Middl | 2022 |
Naltrexone + Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: A Randomized, Controlled Pilot Study.
Topics: Adult; Anti-Obesity Agents; Binge-Eating Disorder; Body Weight; Bupropion; Double-Blind Method; Drug | 2021 |
A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).
Topics: Adult; Anti-Obesity Agents; Bupropion; Cardiovascular Diseases; Delayed-Action Preparations; Dopamin | 2013 |
Bupropion for overweight women with binge-eating disorder: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Body Mass Index; Bulimia; Bupropion; Dopamine Uptake Inhibitors; Double-Blind Method; Female; | 2013 |
Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Blood Glucose; Body Weight; Bupro | 2013 |
Patient-reported quality of life in a randomized placebo-controlled trial of naltrexone/bupropion for obesity.
Topics: Adult; Aged; Anti-Obesity Agents; Bupropion; Drug Combinations; Female; Humans; Male; Middle Aged; N | 2015 |
Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial.
Topics: Aged; Anti-Obesity Agents; Blood Pressure; Body Mass Index; Bupropion; Cardiovascular Diseases; Conf | 2016 |
The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy.
Topics: Adolescent; Adult; Anti-Obesity Agents; Bupropion; Drug Therapy, Combination; Female; Humans; Male; | 2016 |
Naltrexone/Bupropion extended release-induced weight loss is independent of nausea in subjects without diabetes.
Topics: Adult; Anti-Obesity Agents; Body Mass Index; Bupropion; Combined Modality Therapy; Delayed-Action Pr | 2016 |
Method-of-use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity.
Topics: Adolescent; Adult; Body Weight; Bupropion; Delayed-Action Preparations; Dopamine Uptake Inhibitors; | 2017 |
Rational design of a combination medication for the treatment of obesity.
Topics: Adult; Animal Feed; Animals; Antidepressive Agents; Bupropion; Disease Models, Animal; Drug Therapy, | 2009 |
Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo.
Topics: Adolescent; Adult; Appetite; Bupropion; Cohort Studies; Dopamine Uptake Inhibitors; Double-Blind Met | 2009 |
An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects.
Topics: Adult; Bupropion; Cotinine; Counseling; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Femal | 2010 |
Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.
Topics: Adult; Antidepressive Agents; Behavior Therapy; Bupropion; Chemotherapy, Adjuvant; Combined Modality | 2011 |
Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.
Topics: Adult; Antidepressive Agents; Behavior Therapy; Bupropion; Chemotherapy, Adjuvant; Combined Modality | 2011 |
Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.
Topics: Adult; Antidepressive Agents; Behavior Therapy; Bupropion; Chemotherapy, Adjuvant; Combined Modality | 2011 |
Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.
Topics: Adult; Antidepressive Agents; Behavior Therapy; Bupropion; Chemotherapy, Adjuvant; Combined Modality | 2011 |
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Adult; Anti-Obesity Agents; Bupropion; Delayed-Action Preparations; Double-Blind Method; Drug Therap | 2010 |
Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms.
Topics: Adolescent; Adult; Aged; Blood Glucose; Blood Pressure; Bupropion; Cholesterol; Delayed-Action Prepa | 2002 |
Weight gain and cardiovascular risk factors during smoking cessation with bupropion or nicotine.
Topics: Administration, Cutaneous; Adult; Aging; Blood Pressure; Bupropion; Cardiovascular Diseases; Diastol | 2004 |
No evidence for a major role of polymorphisms during bupropion treatment.
Topics: Adult; Bupropion; Dopamine Uptake Inhibitors; Double-Blind Method; Female; Genetic Predisposition to | 2006 |
Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study.
Topics: Adult; Analysis of Variance; Anti-Obesity Agents; Bupropion; Drug Therapy, Combination; Female; Huma | 2007 |
Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women.
Topics: Adult; Anti-Obesity Agents; Bupropion; Dopamine Uptake Inhibitors; Double-Blind Method; Drug Adminis | 2001 |
Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial.
Topics: Adolescent; Adult; Blood Glucose; Blood Pressure; Body Constitution; Bupropion; Cholesterol, HDL; De | 2002 |
42 other studies available for bupropion and Obesity
Article | Year |
---|---|
Naltrexone/bupropion modifies weight, food intake, and Drd2 gene expression in rats.
Topics: Animals; Body Weight; Bupropion; Diet, High-Fat; Eating; Gene Expression; Naltrexone; Obesity; Rats; | 2022 |
Effects of topiramate, bupropion and naltrexone isolated or combined on subcutaneous adipose tissue in obese rats.
Topics: Animals; Bupropion; Humans; Male; Naltrexone; Obesity; Rats; Rats, Wistar; Subcutaneous Fat; Topiram | 2022 |
Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long
Topics: Bupropion; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Glucagon-Like Peptides; Human | 2023 |
[Pharmacotherapy for obesity].
Topics: Anti-Obesity Agents; Bariatric Surgery; Bupropion; Combined Modality Therapy; Drug Combinations; Dru | 2021 |
Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial.
Topics: Aged; Anti-Obesity Agents; Body Weight; Bupropion; Diabetes Mellitus, Type 2; Female; Humans; Hypogl | 2021 |
Early improvement in food cravings are associated with long-term weight loss success in a large clinical sample.
Topics: Adult; Bupropion; Clinical Trials, Phase III as Topic; Craving; Dopamine Uptake Inhibitors; Feeding | 2017 |
Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Binge-Eating Disorder; Bup | 2017 |
Beyond lifestyle interventions: exploring the potential of anti-obesity medications in the UK.
Topics: Anti-Obesity Agents; Bariatric Surgery; Body Weight Maintenance; Bupropion; Health Services; Humans; | 2018 |
Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis.
Topics: Anti-Obesity Agents; Bupropion; Double-Blind Method; Drug Combinations; Humans; Mood Disorders; Nalt | 2019 |
Update on drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
Topics: Anti-Obesity Agents; Bupropion; Delayed-Action Preparations; Drug Combinations; Humans; Naltrexone; | 2019 |
Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity.
Topics: Absorptiometry, Photon; Adiposity; Analysis of Variance; Body Composition; Bupropion; Dopamine Uptak | 2013 |
Therapies for obesity and medication-associated weight gain.
Topics: Animals; Appetite Depressants; Bariatric Surgery; Benzazepines; Bupropion; Chronic Disease; Combined | 2013 |
Effect of combined naltrexone and bupropion therapy on the brain's reactivity to food cues.
Topics: Adolescent; Adult; Appetite; Bupropion; Cues; Diet; Dopamine Uptake Inhibitors; Drug Therapy, Combin | 2014 |
Contrave--a combination of bupropion and naltrexone for weight loss.
Topics: Anti-Obesity Agents; Bupropion; Drug Approval; Drug Combinations; Drug Interactions; Humans; Naltrex | 2014 |
Lorcaserin, phentermine topiramate combination, and naltrexone bupropion combination for weight loss: the 15-min challenge to sort these agents out.
Topics: Benzazepines; Bupropion; Drug Combinations; Drug Prescriptions; Fructose; Humans; Naltrexone; Obesit | 2014 |
Pharmacological treatment of obesity in Europe: waiting for the arrival of the white blackbird.
Topics: Anti-Obesity Agents; Appetite Depressants; Benzazepines; Bupropion; Clinical Trials as Topic; Drug A | 2014 |
Letter to the editor: naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date.
Topics: Anti-Obesity Agents; Bupropion; Humans; Naltrexone; Obesity | 2015 |
Nonincretin drugs in later-stage development.
Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Drug Combinations; Drug Labeling; Drugs, | 2014 |
[Mysimba, an American appetite suppressant and the logic of the single European market].
Topics: Anti-Obesity Agents; Bupropion; Drug Combinations; Humans; Naltrexone; Obesity; Overweight | 2015 |
Review of pharmacotherapy options for the management of obesity.
Topics: Benzazepines; Bupropion; Disease Management; Fructose; Humans; Lactones; Liraglutide; Naltrexone; Ob | 2016 |
Comparison of Diabetes Risk Following Smoking Cessation Treatment Using Varenicline Versus Bupropion Among Obese Smokers.
Topics: Adolescent; Adult; Aged; Bupropion; Cohort Studies; Comorbidity; Diabetes Mellitus, Type 2; Dopamine | 2015 |
Evaluation of the Cardiovascular Risk of Naltrexone-Bupropion: A Study Interrupted.
Topics: Anti-Obesity Agents; Bupropion; Cardiovascular Diseases; Early Termination of Clinical Trials; Femal | 2016 |
Time-to-Event Analysis.
Topics: Anti-Obesity Agents; Bupropion; Cardiovascular Diseases; Early Termination of Clinical Trials; Femal | 2016 |
Company is blamed for early halt of trial into obesity treatment.
Topics: Anti-Obesity Agents; Bupropion; Cardiovascular Diseases; Early Termination of Clinical Trials; Femal | 2016 |
A new era of addiction treatment amplifies the stigma of disease and treatment for individuals with obesity.
Topics: Anti-Obesity Agents; Attitude of Health Personnel; Behavior, Addictive; Bupropion; Drug Therapy, Com | 2016 |
Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management.
Topics: Anti-Obesity Agents; Benzazepines; Body Mass Index; Bupropion; Guidelines as Topic; Humans; Lactones | 2016 |
Improving efficacy of the adjustable gastric band: studies of the use of adjuvant approaches in a rodent model.
Topics: Adipose Tissue, Brown; Animals; Anti-Obesity Agents; Blood Glucose; Body Composition; Body Fat Distr | 2017 |
Obesity Epidemic: Pharmaceutical Weight Loss.
Topics: Anti-Obesity Agents; Benzazepines; Body Mass Index; Bupropion; Drug Combinations; Fructose; Humans; | 2017 |
Strategies to control antipsychotic-induced weight gain.
Topics: Anti-Obesity Agents; Antipsychotic Agents; Awareness; Body Weight; Bupropion; Clinical Competence; F | 2008 |
Is cardiometabolic risk improved by weight-loss drugs?
Topics: Anti-Obesity Agents; Bupropion; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Naltrexo | 2010 |
Miracle pills for weight loss: what is the number needed to treat, number needed to harm and likelihood to be helped or harmed for naltrexone-bupropion combination?
Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Body Mass Index; Bupropion; Delayed-Action Preparation | 2010 |
New obesity pill: new hopes, old fears.
Topics: Anti-Obesity Agents; Antidepressive Agents, Second-Generation; Bupropion; Cardiovascular Diseases; D | 2010 |
Bupropion/naltrexone fixed-dose combination for the treatment of obesity.
Topics: Animals; Bupropion; Clinical Trials as Topic; Drug Combinations; Humans; Naltrexone; Obesity | 2011 |
Drug treatment of obesity.
Topics: Adolescent; Adult; Anti-Obesity Agents; Antidepressive Agents, Second-Generation; Body Weight; Bupro | 2011 |
What cost weight loss?
Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Cyclobutanes; Fructose; Humans; Naltrexone; Obesity; P | 2012 |
Effects of amylin and bupropion/naltrexone on food intake and body weight are interactive in rodent models.
Topics: Animals; Appetite Depressants; Body Composition; Body Weight; Bupropion; Diet; Drug Interactions; Ea | 2013 |
Topiramate for weight reduction in Duchenne muscular dystrophy.
Topics: Adolescent; Anti-Obesity Agents; Antidepressive Agents, Second-Generation; Appetite; Body Weight; Bu | 2005 |
Weight gain, sexual dysfunction, and bupropion.
Topics: Ambulatory Care; Bupropion; Delayed-Action Preparations; Depressive Disorder; Drug Labeling; Humans; | 2005 |
Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice.
Topics: Animals; Behavior, Animal; Body Weight; Bupropion; Dopamine; Dose-Response Relationship, Drug; Drug | 2007 |
Editorial.
Topics: Body Mass Index; Bupropion; Depression; Dopamine Uptake Inhibitors; Health Behavior; Humans; Life St | 2006 |
[Tobacco use prevention and cessation in the dental practice].
Topics: Behavior Therapy; Benzazepines; Bupropion; Dentist-Patient Relations; Health Plan Implementation; Hu | 2007 |
Dopamine-norepinephrine interactions in the development of hyperphagia and obesity following medial hypothalamic lesions.
Topics: Animals; Body Weight; Brain Mapping; Bupropion; Dopamine; Feeding Behavior; Female; Hydroxydopamines | 1986 |